Document:

Exhibit 10.57

EXCHANGE AGREEMENT

BY AND AMONG 

MOTIENT CORPORATION,

MVH HOLDINGS INC., 

AND 

[TSTR STOCKHOLDER] 

Dated as of August ___, 2006 

TABLE OF CONTENTS

	
 
		
 
		
 
		
Page 
	
	
 
	
	
ARTICLE I Purchase and Sale	
 
	
	
 Section	
1.1 
		
Sale of TerreStar Shares and Motient Shares 
		
1 
	
	
 Section	
1.2 
		
Closing 
		
1 
	
	
 Section	
1.3 
		
Deliveries 
		
2 
	
	
 
	
	
ARTICLE II Representations and Warranties of FUND 
		
 
	
	
 Section	
2.1 
		
Organization 
		
3 
	
	
 Section	
2.2 
		
Title to TerreStar Shares 
		
3 
	
	
 Section	
2.3 
		
Authority Relative to this Agreement and the Registration Rights Agreement 
		
 3
	
 Section	
2.4 
		
Consents and Approvals; No Violations 
		
4 
	
	
 Section	
2.5 
		
Purchase Entirely for Own Account 
		
4 
	
	
 Section	
2.6 
		
Reliance Upon Holder’s Representations 
		
4 
	
	
 Section	
2.7 
		
Receipt of Information 
		
5 
	
	
 Section	
2.8 
		
Investor Status; etc 
		
5 
	
	
 Section	
2.9 
		
Liens for Taxes 
		
5 
	
	
 Section	
2.10 
		
Brokers or Finders 
		
5 
	
	
 Section	
2.11 
		
Restricted Securities 
		
5 
	
	
 Section	
2.12 
		
Legends 
		
6 
	
	
 
	
	
ARTICLE III Representations and Warranties of MOTIENT 
		
 
	
	
 Section	
3.1 
		
Corporate Organization; Related Entities 
		
6 
	
	
 Section	
3.2 
		
Capitalization 
		
6 
	
	
 Section	
3.3 
		
Authority Relative to This Agreement 
		
7 
	
	
 Section	
3.4 
		
Consents and Approvals; No Violations 
		
7 
	
	
 Section	
3.5 
		
Reports and Financial Statements 
		
8 
	
	
 Section	
3.6 
		
Absence of Certain Changes or Events 
		
9 
	
	
 Section	
3.7 
		
Litigation 
		
9 
	
	
 Section	
3.8 
		
Compliance with Law 
		
9 
	
	
 Section	
3.9 
		
Absence of Undisclosed Liabilities 
		
10 
	
	
 Section	
3.10 
		
No Default 
		
10 
	
	
 Section	
3.11 
		
Taxes 
		
10 
	
	
 Section	
3.12 
		
Intellectual Property 
		
11 
	
	
 Section	
3.13 
		
Permits 
		
11 
	
	
 Section	
3.14 
		
Contracts 
		
11 
	
	
 Section	
3.15 
		
Insurance 
		
12 
	
	
 Section	
3.16 
		
Ownership of TerreStar Common Stock 
		
12 
	
	
 Section	
3.17 
		
Purchase Entirely for Own Account 
		
12 
	
	
 Section	
3.18 
		
Reliance Upon Holder’s Representations 
		
12 
	
	
 Section	
3.19 
		
Receipt of Information 
		
12 
	
	
 Section	
3.20 
		
Investor Status; etc 
		
12 
	
	
 Section	
3.21 
		
Brokers or Finders 
		
13 
	

i

	
 Section	
3.22 
		
Restricted Securities 
		
13 
	
	
 Section	
3.23 
		
Issuances Exempt 
		
13 
	
	
 Section	
3.24 
		
No Integrated Offering 
		
13 
	
	
 
	
	
ARTICLE IV Additional Agreements 
		
 
	
	
 Section	
4.1 
		
HSR Act and FCC Approval 
		
13 
	
	
 Section	
4.2 
		
Blue Sky Laws 
		
14 
	
	
 Section	
4.3 
		
Compliance with TerreStar Documents 
		
14 
	
	
 Section	
4.4 
		
No Transfers; No Alternative Transactions 
		
15 
	
	
 Section	
4.5 
		
Commercially Reasonable Efforts 
		
15 
	
	
 Section	
4.6 
		
Public Announcements 
		
16 
	
	
 
	
	
ARTICLE V Conditions to Closing of MOTIENT and SUB 
		
 
	
	
 Section	
5.1 
		
Representations and Warranties 
		
16 
	
	
 Section	
5.2 
		
Performance 
		
16 
	
	
 Section	
5.3 
		
Intentionally Omitted 
		
16 
	
	
 Section	
5.4 
		
Certificates and Documents 
		
16 
	
	
 Section	
5.5 
		
Compliance Certificate 
		
16 
	
	
 Section	
5.6 
		
Final Order of FCC and Industry Canada Approval 
		
17 
	
	
 Section	
5.7 
		
Intentionally Omitted 
		
17 
	
	
 Section	
5.8 
		
Intentionally Omitted 
		
17 
	
	
 Section	
5.9 
		
FIRPTA Certificate 
		
17 
	
	
 Section	
5.10 
		
Amended TerreStar Stockholders’ Agreement 
		
17 
	
	
 Section	
5.11 
		
MSV Exchange Agreement 
		
17 
	
	
 Section	
5.12 
		
Columbia/Spectrum Exchange Agreements 
		
17 
	
	
 
	
	
ARTICLE VI Conditions to Closing of FUND 
		
 
	
	
 Section	
6.1 
		
Representations and Warranties 
		
17 
	
	
 Section	
6.2 
		
Performance 
		
18 
	
	
 Section	
6.3 
		
Opinion of Motient’s Counsel 
		
18 
	
	
 Section	
6.4 
		
Certificates and Documents 
		
18 
	
	
 Section	
6.5 
		
Compliance Certificate 
		
18 
	
	
 Section	
6.6 
		
FCC and Industry Canada Approvals 
		
18 
	
	
 Section	
6.7 
		
Intentionally Omitted 
		
18 
	
	
 Section	
6.8 
		
Effective Registration Statement 
		
18 
	
	
 Section	
6.9 
		
Registration Rights Agreement 
		
18 
	
	
 Section	
6.10 
		
Holder Exchange Agreements 
		
18 
	
	
 
	
	
ARTICLE VII INDEMNIFICATION 
		
 
	
	
 Section	
7.1 
		
Survival of Representations and Warranties 
		
18 
	
	
 Section	
7.2 
		
Obligation to Indemnify 
		
18 
	
	
 Section	
7.3 
		
Indemnification Procedures 
		
19 
	
	
 Section	
7.4 
		
Notices and Payments 
		
20 
	
	
 Section	
7.5 
		
Limited Remedy 
		
20 
	
	
 
	
	
ARTICLE VIII Miscellaneous 
		
 
	
	
 Section	
8.1 
		
Termination 
		
21 
	

ii

	
 	
Section 
		
8.2 
		
Survival 
		
21 
	
	
 	
Section 
		
8.3 
		
Expenses 
		
22 
	
	
 	
Section 
		
8.4 
		
Counterparts; Effectiveness 
		
22 
	
	
 	
Section 
		
8.5 
		
Governing Law 
		
22 
	
	
 	
Section 
		
8.6 
		
Notices 
		
22 
	
	
 	
Section 
		
8.7 
		
Assignment; Binding Effect 
		
23 
	
	
 	
Section 
		
8.8 
		
Severability 
		
23 
	
	
 	
Section 
		
8.9 
		
Entire Agreement; Non-Assignability; Parties in Interest 
		
23 
	
	
 	
Section 
		
8.10 
		
Headings 
		
23 
	
	
 	
Section 
		
8.11 
		
Certain Definitions 
		
23 
	
	
 	
Section 
		
8.12 
		
Amendments and Waivers 
		
24 
	
	
 	
Section 
		
8.13 
		
Specific Performance 
		
24 
	
	
 	
Section 
		
8.14 
		
Exclusive Jurisdiction 
		
24 
	
	
 	
Section 
		
8.15 
		
Waiver of Jury Trial 
		
24 
	

	
Schedule A 
		
Motient Disclosure Schedule 
	
	
Exhibit A 
		
Registration Rights Agreement 
	
	
Exhibit B 
		
Form of Amended and Restated TerreStar Stockholders’ Agreement 
	
	
Exhibit C 
		
Form of Legal Opinion of Counsel to Motient 
	

iii

EXCHANGE AGREEMENT

THIS EXCHANGE AGREEMENT (this “Agreement”) is made and entered into as of August ___, 2006 by and among Motient Corporation, a Delaware corporation (“Motient”), MVH Holdings Inc., a Delaware
corporation and indirect, wholly-owned subsidiary of Motient
(“Sub”), and [TSTR Stockholder] (“Holder”). 

RECITALS:

WHEREAS, subject to the terms and conditions hereof, at the Closing (as defined below) Motient, through Sub, intends to purchase from Holder, and Holder intends to sell to Sub, (i) 
_______________ shares of common stock, par value
$0.001 per share (the “TerreStar Networks Shares”) of TerreStar Networks, Inc.(“TerreStar”) and ___________ shares of common stock par value $0.01 per share (the “TerreStar
Bermuda Shares” and, together with the TerreStar Networks Shares, the “TerreStar Shares”) of TerreStar Networks Bermuda Ltd. owned by Holder, in exchange for ) _____________ shares (the “Motient
Shares”) of common stock, par value $0.01 per share (“Motient Common Stock”), of Motient, in each case as appropriately adjusted for any stock split, combination, reorganization, recapitalization,
reclassification, stock dividend, stock distribution or similar event declared or effected prior to the Closing; provided, that no adjustment shall be made for the Rights Offering (as defined below). 

AGREEMENT:

NOW, THEREFORE, in consideration of the covenants and representations set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 

ARTICLE I

PURCHASE AND SALE

Section 1.1     Sale of TerreStar Shares and Motient Shares.  Subject to the terms and conditions hereof and in reliance upon the representations, warranties and agreements contained herein, at the Closing, Holder will purchase from Motient, and
Motient shall issue and sell to Holder, the Motient Shares, and Motient will purchase from Holder, and Holder shall sell to Sub, the TerreStar Shares.

Section 1.2     Closing.  The Closing (the “Closing”) of the purchase and sale of the TerreStar Shares in exchange for the Motient Shares shall be held at the offices of Andrews Kurth LLP, 450 Lexington Avenue, New York,
New York on the first business day immediately following the day on which the last to be fulfilled or waived of the conditions set forth in Articles V and VI (other than those conditions that by their nature are to be satisfied at the Closing, but
subject to fulfillment or waiver of those conditions), shall be fulfilled or waived in accordance herewith; or (b) at such other time, date or place as Motient and Holder may agree in writing. The date on which the Closing occurs is hereinafter
referred to as the “Closing Date.” 

Section 1.3     Deliveries.

(a)     Simultaneously with the execution of this Agreement, Motient and Holder shall execute and deliver (i) the Registration Rights Agreement in the form attached as Exhibit A hereto (the “Registration Rights
Agreement”), (ii) Amendment No. 2 to the TerreStar Networks Inc. Stockholders’ Agreement; and (iii) the Amended and Restated TerreStar Stockholders’ Agreement dated as of May 6, 2006 (the “Amended TerreStar
Stockholders’ Agreement”) in the form attached as Exhibit B, both (ii) and (iii) to be effective in accordance with their terms.

(b)     At the Closing: 

(i)     Holder shall deliver to Motient and/or Sub the following (collectively, the “Holder Closing Deliveries”): 

(ii)     certificates registered in Holder’s name representing the TerreStar Shares or an affidavit of lost certificate with respect to any lost, missing or destroyed certificate in form reasonably satisfactory to Motient;

(iii)     a duly executed stock power evidencing the transfer of the TerreStar Shares from Holder to Sub and in such form reasonably satisfactory to Motient or an affidavit of lost certificate with respect to any lost, missing or destroyed certificate
in form reasonably satisfactory to Motient as shall be effective to vest in Motient good and valid title to the TerreStar Shares, free and clear of any Lien (as defined below) other than Securities Law Encumbrances (as defined below) or pursuant to
the TerreStar Documents (as defined below); 

(iv)     [a certificate of good standing for Holder from the Secretary of State of the State of

[________]; and]

(v)     an affidavit certifying as to Holder’s non-foreign status in accordance with the requirements of Section 1.1445 -2(b) of the Internal Revenue Service Treasury Regulations. 

(c)     Motient and/or Sub shall deliver to Holder the following (collectively, the “Motient Closing Deliveries”): 

(i)     a certificate registered in Holder’s name representing the Motient Shares;

(ii)     an effective registration statement (the “Registration Statement”) registering the resale by Holder or the Holder’s beneficial owners of the Motient Shares;

(iii)     certified resolutions of Motient and Sub’s Board of Directors approving this Agreement and the transactions contemplated hereby; and

(iv)     a certificate of good standing for Motient and Sub from the Secretary of State of the State of Delaware. 

2

ARTICLE II

REPRESENTATIONS AND WARRANTIES OF FUND

Holder represents and warrants to Motient and Sub, as follows:

Section 2.1     Organization.  [Holder is a limited [partnership][liability company] duly organized, validly existing and in good standing under the laws of the State of [Delaware] and Holder has the requisite limited [partnership][liability
company] power and authority to own or lease its properties and to carry on its business as is presently being conducted. Holder is duly qualified to do business as a foreign limited [partnership][liability company], and is in good standing, in each
jurisdiction in which the ownership of its properties or the conduct of its business requires such qualification, except for failures, if any, to be so qualified which individually or in the aggregate have not had and could not reasonably be
expected to have a Holder Material Adverse Effect.] A “Holder Material Adverse Effect” means a material adverse effect respecting the ability of Holder to consummate the transactions contemplated by this
Agreement or fulfill the conditions to Closing set forth herein, except to the extent that such adverse effect results from (i) general economic, regulatory or political conditions or changes therein in the United States or the other countries in
which such party operates; (ii) financial or securities market fluctuations or conditions; or (iii) changes in, or events or conditions affecting, the wireless telecommunications industry generally.

Section 2.2     Title to TerreStar Shares. As of the date hereof and at all times until and including at the Closing, Holder owns, of record and beneficially, the TerreStar Shares free and clear of any and all option, call, contract, commitment,
mortgage, pledge, security interest, encumbrance, lien, Tax, claim or charge of any kind or right of others of whatever nature (collectively, a “Lien”) of any kind, other than pursuant to applicable securities laws
(“Securities Law Encumbrances”) or the TerreStar Documents (defined below). Upon the Closing, (x) Sub shall be vested with good and valid title to the TerreStar Shares, free and clear of any Liens of any kind (other than
Securities Law Encumbrances or the TerreStar Documents) and (y) Holder shall not own, of record or beneficially, or have, by conversion, warrant, option or otherwise, any right to interest in or agreement to acquire any shares of TerreStar common
stock[, other than options to purchase shares of TerreStar common stock]. The “TerreStar Documents” means the TerreStar Stockholders’ Agreement dated May 11, 2005, as amended (the “TerreStar Stockholders’
Agreement”), the TerreStar Parent Transfer/Drag Along Agreement dated May 11, 2005, the Certificate of Incorporation of TerreStar Networks Inc. and the Amended and Restated Bylaws of TerreStar Networks, Inc., as the same may be amended
from time to time. 

Section 2.3     Authority Relative to this Agreement and the Registration Rights Agreement. Holder has the requisite [limited partnership][limited liability company][corporate] power and authority to execute and deliver this Agreement and the
Registration Rights Agreement and to consummate the transactions contemplated hereby and thereby. The execution and delivery of this Agreement and the Registration Rights Agreement by Holder, and the consummation by Holder of the transactions
contemplated hereby have been duly authorized by the Holder, and no other proceedings on the part of Holder are necessary to authorize this Agreement or for Holder to consummate the transactions contemplated hereby. This Agreement has been duly and
validly executed and delivered by Holder and, assuming the due authorization,
execution and delivery thereof by Motient and Sub, constitutes the valid and binding obligation of Holder, enforceable against it in accordance with its terms.

3

 Section 2.4    Consents and Approvals; No Violations. Except in connection or in order to comply with the applicable provisions of (a) the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) and, if
necessary, similar foreign competition or Antitrust Laws, (b) the filing of the Registration Statement under the Securities Act of 1933, as amended (the “Securities Act”), (c) filings or approvals required under state
securities or “blue sky” laws, and (d) the Communications Act of 1934, as amended, and the rules, regulations or policies of the Federal Communications Commission and any successor thereto (“FCC”) and Industry
Canada and any successor thereto (collectively, the “Communications Laws”), neither the execution and delivery of this Agreement or the Registration Rights Agreement, nor the consummation of the transactions contemplated
hereby or thereby will, conflict with, or result in any violation of, or default under (with or without notice or lapse of time, or both), or give rise to a right of termination, cancellation or acceleration of any obligation or loss of a benefit
under (i) any provision of the organizational documents of Holder, (ii) any material mortgage, indenture, lease, contract or other agreement or instrument, permit, concession, franchise, license, judgment, order, decree, statute, law, ordinance,
rule or regulation applicable to Holder or its respective properties or assets, including but not limited to the TerreStar Documents. Except in connection or in order to comply with the applicable provisions of (a) the HSR Act and, if necessary,
similar foreign competition or Antitrust Laws, (b) the filing of the Registration Statement under the Securities Act, (c) filings or approvals required under state securities or “blue sky” laws, and (d) the Communications Laws, no consent,
approval, order or authorization of, or registration, declaration or filing with, any federal, state, local or foreign court, arbitral tribunal, administrative agency or commission or other governmental or other regulatory body, authority or
administrative agency or commission (collectively, a “Governmental Entity”), is required by or with respect to Holder in connection with the execution and delivery of this Agreement or the Registration Rights Agreement by
Holder or the consummation by Holder of the transactions contemplated hereby or thereby, except for such consents, authorizations, filings, approvals and registrations which, if not obtained or made, would not have a Holder Material Adverse
Effect.

Section 2.5     Purchase Entirely for Own Account. The Motient Shares will be acquired for investment for Holder’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, in each case,
in violation of applicable securities laws, and Holder has no present intention of selling, granting any participation in, or otherwise distributing such Motient Shares except in compliance with applicable securities laws.  It is understood that
nothing herein shall prevent Holder from distributing the Motient Shares to its beneficial owners, in compliance with Section 5.1 of the Registration Rights Agreement and applicable securities laws.

Section 2.6     Reliance Upon Holder’s Representations. Holder understands that the Motient Shares will not be registered for issuance to Holder under the Securities Act and the sale provided for in this Agreement and Motient’s issuance
of the Motient Shares hereunder will be made in reliance upon an exemption from registration under the Securities Act pursuant to Section 4(2) thereof, and that, in such case, Motient’s reliance on such exemption will be based on Holder’s
representations set forth herein. 

4

Section 2.7     Receipt of Information. Holder believes it has received all the information it considers necessary or appropriate for deciding whether to acquire Motient Shares.  Holder further represents that it has had an opportunity to ask
questions and receive answers from Motient regarding the terms and conditions of the offering of Motient Shares and the business and financial condition of Motient and to obtain additional information (to the extent Motient possessed such
information or could acquire it without unreasonable effort or expense) necessary to verify the accuracy of any information furnished to it or which it had access. The foregoing, however, does not limit or modify the representations or warranties of
Motient in this Agreement or the right of Holder to rely upon such representations or warranties. Holder has received, nor is it relying on, any representations or warranties from Motient or Sub, other than as provided herein; provided that the
foregoing shall not affect any right Holder may have on account of fraud. 

Section 2.8     Investor Status; etc. Holder certifies and represents to Motient that it is an “accredited investor” as defined in Rule 501 of Regulation D promulgated under the Securities Act and was not organized for the purpose of
acquiring the Motient Shares. Holder’s financial condition is such that it is able to bear the risk of holding the Motient Shares for an indefinite period of time and the risk of loss of its entire investment. Holder has sufficient knowledge
and experience in investing in companies similar to Motient so as to be able to evaluate the risks and merits of its investment in Motient.

Section 2.9     Liens for Taxes.  There are no Liens arising from or related to Taxes (defined below) on or pending against the TerreStar Shares other than Liens (defined below) for Taxes that are not yet due and payable.
“Tax” means any and all federal, state, local, foreign or other tax of any kind (together with any and all interest, penalties, additions to tax and additional amounts imposed with respect thereto) imposed by any Tax
Authority, including taxes on or with respect to income, alternative minimum, accumulated earnings, personal holding company, capital, transfer, stamp, franchises, windfall or other profits, gross receipts, property, sales, use, capital stock,
payroll, employment, unemployment, social security, workers' compensation or net worth, and taxes in the nature of excise, withholding, ad valorem or value added. 

Section 2.10   Brokers or Finders. Holder has not incurred, nor will it incur, directly or indirectly, any liability for brokerage or finders’ fees or agents’ commissions or investment bankers’ fees or any similar charges in
connection with this Agreement or any transaction contemplated hereby. 

Section 2.11   Restricted Securities. Holder understands that the Motient Shares may not be sold, transferred or otherwise disposed of without registration under the Securities Act or an exemption therefrom, and that in the absence of an
effective registration statement covering the Motient Shares or an available exemption from registration under the Securities Act, such Motient Shares must be held indefinitely.  In particular, Holder is aware that such Motient Shares may not be
sold pursuant to Rule 144 or Rule 145 promulgated under the Securities Act unless all of the conditions of the applicable rule are met. Among the conditions for use of Rules 144 and 145 is the availability of current information to the public about
Motient. 

5

Section 2.12   Legends.  It is understood that the certificates evidencing the Motient Shares will bear one or both of the following legends: 

(a)     “These securities have not been registered under the Securities Act of 1933, as amended. They may not be sold, offered for sale, pledged or hypothecated in the absence of a registration statement in effect with respect to the securities
under such Act or an opinion of counsel satisfactory to Motient Corporation that such registration is not required.” 

(b)     Any legend required by the laws of the State of Delaware or other
jurisdiction.

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF MOTIENT

Except as otherwise specifically provided in the Disclosure Schedule of Motient attached hereto and incorporated herein by reference which clearly identifies the relevant section of this Agreement (the “Motient Disclosure
Schedule”), Motient and Sub, jointly and severally, represent and warrant to Holder, as follows: 

Section 3.1     Corporate Organization; Related Entities.  Motient and Sub are corporations duly organized, validly existing and in good standing under the laws of the State of Delaware and each has the requisite corporate power and authority to
own or lease its properties and to carry on its business as it is presently being conducted.  Motient and Sub are duly qualified to do business as a foreign corporation, and are in good standing, in each jurisdiction in which the ownership of their
properties or the conduct of their business requires such qualification, except for failures, if any, to be so qualified which individually or in the aggregate have not had and could not reasonably be expected to have a Motient Material Adverse
Effect. The copies of the certificates of incorporation and bylaws of Motient and Sub heretofore made available to Holder are complete and current copies of such instruments as presently in effect. A “Motient Material Adverse
Effect” means a material adverse effect respecting (a) the business, assets and liabilities (taken together) or financial condition of Motient and its subsidiaries on a consolidated basis or (b) the ability of Motient to consummate the
transactions contemplated by this Agreement or fulfill the conditions to Closing set forth herein, except to the extent (in the case of either clause (a) or clause (b) above) that such adverse effect results from (i) general economic, regulatory or
political conditions or changes therein in the United States or the other countries in which such party operates; (ii) financial or securities market fluctuations or conditions; or (iii) changes in, or events or conditions affecting, the wireless
telecommunications industry generally. 

Section 3.2     CapitalizationAs of the date of this Agreement, the authorized capital stock of Motient consists of (i) 200,000,000 shares of Motient’s common stock, par value $0.01 per share (the “Motient Common
Stock”), _______________ of which are issued and outstanding and (ii) 5,000,000 shares of preferred stock, par value $0.01 per share (“Motient Preferred Stock”),
450,000 of which are designated as Series A 

6

Cumulative Convertible Preferred Stock and 90,000 of which are issued and outstanding
and 500,000 of which are
designated as Series B Cumulative Convertible Preferred Stock and 318,500 of which are issued and outstanding. Motient has no other designations of Motient Preferred Stock. As of the date of this Agreement, (x) ___________ shares of Motient
Common Stock are reserved for issuance pursuant to Motient’s stock option plans (each a “Motient Stock Option Plan”), a list of which is set forth on Schedule 3.2 of the Motient Disclosure Schedule, (x)
_______________ shares of Motient Common Stock are reserved for issuance upon the exercise of outstanding warrants to purchase shares of Motient Common Stock, [(y) 2,500,000 shares of Motient Common Stock are reserved for issuance upon the
exercise of outstanding non-transferable common stock purchase rights held by certain of the holders of Motient Common Stock as of December 17, 2004 in a rights offering (the “Rights Offering”)] and (C) certain Exchange
Agreements dated as of the date hereof by and between Motient, Sub and certain holders of TerreStar Shares. All the issued and outstanding shares of Motient’s capital stock have been duly authorized and validly issued and are fully paid,
nonassessable and free of statutory preemptive rights and contractual stockholder preemptive rights, with no personal liability attaching to the ownership thereof. Except the Motient Preferred Stock, pursuant to the Motient Stock Option Plan and as
set forth in (x) and (y) above, Motient (i) does not have and is not bound by any outstanding subscriptions, options, voting trusts, convertible securities, warrants, calls, commitments or agreements of any character or kind calling for the
purchase, issuance or grant of any additional shares of its capital stock or restricting the transfer of its capital stock and (ii) is not a party to any voting trust or other agreement or understanding with respect to the voting of the capital
stock or other equity securities of Motient. 

(b)     The Motient Shares have been duly and validly authorized, and, when issued upon the terms hereof, will be fully paid, nonassessable and free of statutory preemptive rights and contractual stockholder preemptive rights, with no personal liability
attaching to the ownership thereof. 

Section 3.3     Authority Relative to This Agreement. Motient and Sub have the requisite corporate power and authority to execute and deliver this Agreement and the Registration Rights Agreement and to consummate the transactions contemplated
hereby and thereby. The execution and delivery of this Agreement and the Registration Rights Agreement by Motient and, if applicable, Sub and the consummation by Motient and, if applicable, Sub of the transactions contemplated hereby and thereby
have been duly authorized by Motient’s and, if applicable, Sub’s Board of Directors, and no other corporate or stockholder proceedings on the part of Motient or Sub are necessary to authorize this Agreement or for Motient or Sub to
consummate the transactions contemplated hereby. This Agreement and the Registration Rights Agreement have been duly and validly executed and delivered by Motient and, if applicable, Sub and, assuming the due authorization, execution and delivery
thereof by Holder, constitute the valid and binding obligations of Motient and, if applicable, Sub, enforceable against Motient and, if applicable, Sub in accordance with its terms. 

Section 3.4     Consents and Approvals; No Violations. Except in connection or in order to comply with the applicable provisions of (a) the HSR Act, and if necessary, similar foreign competition or Antitrust Laws, (b) the filing of the
Registration Statement under the Securities Act, (c) filings or approvals required under state securities or “blue sky” laws, and (d) the Communications Laws, neither the execution and delivery of this Agreement, nor the consummation of
the transactions contemplated hereby will, conflict with, or result in any

7

violation of, or default under (with or without notice or lapse of time, or both), or give rise to a right of termination, cancellation or acceleration of any obligation or loss of a benefit under (i) any provision of the organizational documents of
Motient or Sub, (ii) any material mortgage, indenture, lease, contract or other agreement or instrument, permit, concession, franchise, license, judgment, order, decree, statute, law, ordinance, rule or regulation applicable to Motient or Sub or its
properties or assets, including but not limited to the TerreStar Documents. Except in connection or in order to comply with the applicable provisions of (a) the HSR Act, and if necessary, similar foreign competition or Antitrust Laws, (b) the filing
of the Registration Statement under the Securities Act, (c) filings or approvals required under state securities or “blue sky” laws, and (d) the Communications Laws, no consent, approval, order or authorization of, or registration,
declaration or filing with, any Governmental Entity is required by or with respect to Motient or Sub in connection with the execution and delivery of this Agreement by Motient or Sub or the consummation by Motient or Sub of the transactions
contemplated hereby except for such consents, authorizations, filings, approvals and registrations which, if not obtained or made, would not have a Motient Material Adverse Effect. 

Section 3.5     Reports and Financial Statements.

(a)     Except as set forth on Schedule 3.5(a) of the Motient Disclosure Schedule, Motient has timely filed all reports required to be filed with the SEC pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange
Act”) or the Securities Act since January 1, 2004 (collectively, the “Motient SEC Reports”), and has previously made available to Holder true and complete copies of all such Motient SEC Reports. Such Motient SEC
Reports, as of their respective dates (or if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), complied in all material respects with the applicable requirements of the Securities Act and the
Exchange Act, as the case may be, and none of such Motient SEC Reports, as of their respective dates (or if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), contained any untrue statement of a
material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.  The consolidated financial statements of Motient
included in the Motient SEC Reports have been prepared in accordance with GAAP consistently applied throughout the periods indicated (except as otherwise noted therein or, in the case of unaudited statements, as permitted by Form 10-Q of the SEC)
and fairly present (subject, in the case of unaudited statements, to normal, recurring year-end adjustments and any other adjustments described therein), in all material respects, the consolidated financial position of Motient and its consolidated
subsidiaries as at the dates thereof and the consolidated results of operations and cash flows of Motient and its consolidated subsidiaries for the periods then ended. Except as disclosed in the Motient SEC Reports there has been no change in any of
the significant accounting (including Tax accounting) policies or procedures of Motient since December 31, 2005. 

(b)     Except as set forth on Schedule 3.5(b) of the Motient Disclosure Schedule, Motient maintains a system of internal accounting controls sufficient to provide reasonable assurances that: (i)
transactions are executed in accordance with management’s general or specific
authorization; (ii) transactions are recorded as necessary to permit preparation
of financial statements in conformity with GAAP or any other criteria  

8

applicable
to such statements
and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at
reasonable intervals and appropriate action is taken with respect to any differences. 

(c)     Since January 1, 2005, neither Motient nor, to Motient’s knowledge, any director, officer, employee, auditor, accountant or representative of Motient has received or otherwise had or obtained knowledge of any complaint, allegation,
assertion or claim, in writing, regarding the accounting or auditing practices, procedures, methodologies or methods of Motient or Motient’s internal accounting controls, including any complaint, allegation, assertion or claim that Motient has
engaged in questionable accounting or auditing practices.  No attorney representing Motient, whether or not employed by Motient, has reported “evidence of a material violation” (as defined in 17 CFR Part 205) to Motient’s board of
directors or any committee thereof or to any director or officer of Motient. 

Section 3.6     Absence of Certain Changes or Events. Except as set forth in the Motient SEC Reports filed prior to the date of this Agreement or as set forth on Schedule 3.6 of the Motient Disclosure Schedule, since December 31, 2005, (i)
Motient has conducted its business and operations in the ordinary course of business and consistent with past practices and (ii) there has not been any fact, event, circumstance or change affecting or relating to Motient which has had or could
reasonably be expected to have a Motient Material Adverse Effect or as set forth on Schedule 3.6 to the Motient Disclosure Schedule.  Except as set forth on Schedule 3.6 of the Motient Disclosure Schedule or as could not reasonably be
expected to represent a Motient Material Adverse Effect, the transactions contemplated by this Agreement will not constitute a change of control under or require the consent from or the giving of notice to a third party pursuant to the terms,
conditions or provisions of any Motient Contract (defined below). 

Section 3.7     Litigation.  Except for litigation disclosed in the notes to the audited financial statements of Motient as of and for the period ended December 31, 2005, or in Motient SEC Reports filed subsequent thereto but prior to the date of
this Agreement, as of the date hereof, there is no suit, action, proceeding or investigation pending or, to the knowledge of Motient, threatened against Motient or with respect to which Motient could be required to provide indemnification or to
otherwise contribute to liabilities or damages relating thereto, the outcome of which has had or could reasonably be expected to have a Motient Material Adverse Effect; nor is there any judgment, decree, injunction, rule or order of any Governmental
Entity outstanding against Motient having, or which has had or could reasonably be expected to have a Motient Material Adverse Effect. 

Section 3.8     Compliance with Law.  Motient has not violated any Laws and is in compliance with all Laws, other than where such violation or noncompliance, individually or in the aggregate, has not had and could not reasonably be expected to
have a Motient Material Adverse Effect. Motient has not received any notice to the effect that, or otherwise been advised that or is aware that, Motient is not in such compliance with any Laws, and Motient has no knowledge that any existing
circumstances are reasonably likely to result in such violations of any Laws. 

9

Section 3.9     Absence of Undisclosed Liabilities.  Except for liabilities or obligations which are accrued or reserved against in Motient’s consolidated financial statements (or reflected in the notes thereto) as of and for the period
ended December 31, 2005 as included in the Motient SEC Reports or which were incurred after December 31, 2005 in the ordinary course of business and consistent with past practice, Motient has no liabilities or obligations (whether absolute, accrued,
contingent or otherwise) of a nature required by GAAP to be reflected in a balance sheet (or reflected in the notes thereto) or which have had or could reasonably be expected to have a Motient Material Adverse Effect. 

Section 3.10   No Default. As of the date of this Agreement, Motient is not in breach or violation of, or in default under (and no event has occurred which with notice or lapse of time or both would constitute such a breach, violation or
default), any term, condition or provision of (a) its certificate of incorporation or bylaws, or (b) (x) any order, writ, decree, statute, rule or regulation of any Governmental Entity applicable to Motient or any of its properties or assets or (y)
any agreement required to be filed as a “Material Contract” as an exhibit to Motient’s Annual Report on Form 10-K for the year ended December 31, 2005 or any periodic Exchange Act report required to be filed since then (a
“Motient Contract”), except in the case of this clause (b), which breaches, violations or defaults, individually or in the aggregate, have not had and could not reasonably be expected to have a Motient Material Adverse
Effect. 

Section 3.11   Taxes.  Except as would not reasonably be expected to have a Motient Material Adverse Effect: 

(a)     Motient has timely filed all Tax Returns required to be filed by them (taking into account all applicable extensions) and all such Tax Returns are true, correct and complete in all respects. 

(b)     Motient has paid all Taxes due and payable. 

(c)     There is no pending or, to the knowledge of Motient, threatened examination, investigation, audit, suit, action, claim or proceeding relating to Taxes of Motient. 

(d)     Motient has not received notice of a determination by any taxing or other Governmental Entity that Taxes are owed by Motient (such determination being referred to as a “Tax Deficiency”) and, to the knowledge of Motient,
no Tax Deficiency is proposed or threatened. 

(e)     All Tax Deficiencies asserted against Motient have been paid or finally settled and all amounts asserted in any Tax Deficiency to be owed have been paid. 

(f)     There are no Liens arising from or related to Taxes on or pending against Motient or any of its properties other than statutory Liens for Taxes that are not yet due and payable. 

(g)     As used in this Agreement, “Tax Return” means any return, report or similar statement (including any attached schedules) required to be filed with respect to Taxes and any information return, claim for refund, amended
return, or declaration of estimated Taxes. 

10

Section 3.12   Intellectual Property.

(a)     Motient owns or holds licenses or otherwise has such rights to use, sell, license or dispose of all of the intellectual property rights used in the conduct of the business of Motient as currently conducted, with such exceptions as individually
or in the aggregate have not had and could not reasonably be expected to have a Motient Material Adverse Effect. 

(b)     With such exceptions as individually or in the aggregate have not had and could not reasonably be expected to have a Motient Material Adverse Effect, (i) the operation of Motient’s business and the manufacture, marketing, use, sale,
licensure or disposition of any Intellectual Property in the manner currently used, sold, licensed or disposed of by Motient does not and will not infringe on the proprietary rights of any person, nor has such an infringement been alleged within six
years preceding the date of this Agreement (other than such as have been resolved); (ii) there is no pending or threatened claim or litigation challenging or questioning the validity, ownership or right to use, sell, license or dispose of any such
Intellectual Property in the manner in which currently used, sold, licensed or disposed of by Motient, nor is there a valid basis for any such claim or litigation, nor has Motient received any notice asserting that the proposed operation of
Motient’s business or the use, sale, license or disposition by Motient of any of the Intellectual Property of Motient conflicts or will conflict with the rights of any other party, nor is there a valid basis for any such assertion in each case;
and (iii) none of the Intellectual Property used in the conduct of the business of Motient as currently conducted is being infringed by any person and Motient has not asserted any claim of infringement, misappropriation or misuse within the past six
years. 

Section 3.13   Permits.  Motient has, and is in compliance with, all Motient Permits required to conduct its business as now being conducted, except any such Motient Permit the absence of which, individually or in the aggregate, has not had and
could not reasonably be expected to have a Motient Material Adverse Effect (“Motient Material Permits”). All Motient Material Permits are valid and in full force and effect.  There is not now pending, or to the knowledge of
Motient, threatened, any action by any person or by or before any Governmental Entity to revoke, cancel, rescind, modify or refuse to renew any Motient Material Permits and, other than as set forth on Schedule 3.13 of the Motient Disclosure
Schedule, there exist no facts or circumstances that would reasonably be expected to give rise to such action.  “Motient Permits” means all licenses, permits, franchises, approvals, authorizations, certificates,
registrations, consents or orders of, or filings with, any Governmental Entity used or held for use in the operation of Motient’s business and all other rights and privileges granted by a Governmental Entity necessary to allow Motient to own
and operate its business without any violation of law. 

Section 3.14   Contracts.  All Motient Contracts that are material to the business or operations of Motient taken as a whole have been filed as exhibits to Motient’s
Annual Report on 10-K for the year ended December 31, 2005 or any periodic
Exchange Act report required to be filed since then, are valid and binding
obligations of Motient, and, to the knowledge of Motient, the valid and binding
obligation of each other party thereto, except such Motient Contracts that, if
not so valid and binding, individually or in the aggregate, have not had and
could not reasonably be expected to have a Motient Material Adverse Effect.
Neither Motient nor, to the 

11

knowledge of Motient, any other party thereto, is in violation of or in default
in respect of, nor
has there occurred an event or condition, that with the passage of time or giving of notice (or both), would constitute a default under or permit the termination of, any such Motient Contract except such violations or defaults under or terminations
that, individually or in the aggregate, have not had and could not reasonably be expected to have a Motient Material Adverse Effect. 

Section 3.15   Insurance. Motient’s insurance policies are in all respects in full force and effect in accordance with their terms, no notice of cancellation has been received, and there is no existing default or event that, with the
giving of notice or lapse of time or both, would constitute a default thereunder.  Motient has made available to Holder true and correct copies of all insurance policies maintained by Motient as of the date of this Agreement.

Section 3.16   Ownership of TerreStar Common Stock. As of the date hereof, Motient and its subsidiaries own an aggregate of [19,551,697] shares of TerreStar common stock and immediately prior to the Closing Motient and its subsidiaries will own
not less than [19,551,697] shares of TerreStar common stock (in each case as appropriately adjusted for any stock split, combination, reorganization, recapitalization, reclassification, stock dividend, stock distribution or similar event with
respect to the TerreStar common stock that is declared or effected prior to the Closing).

Section 3.17   Purchase Entirely for Own Account.  The TerreStar Shares to be transferred to Motient will be acquired for investment for Motient’s own account, not as a nominee or agent, and not with a view to the resale or distribution of
any part thereof, in each case, in violation of applicable securities laws, and Motient has no present intention of selling, granting any participation in, or otherwise distributing the same except in compliance with applicable securities laws. 

Section 3.18   Reliance Upon Holder’s Representations.  Motient understands that TerreStar Shares will not be registered under the Securities Act and the sale provided for in this Agreement will be made in reliance upon an exemption from
registration under the Securities Act, and that, in such case, Holder’s reliance on such exemption will be based on Motient and Sub’s representations set forth herein. 

Section 3.19   Receipt of Information. Motient and Sub believe that they have received all the information it considers necessary or appropriate for deciding whether to acquire the TerreStar Shares. Motient further represents that it has had an
opportunity to ask questions and receive answers from Holder regarding the terms and conditions of the TerreStar Shares and the business and financial condition of TerreStar and to obtain additional information (to the extent Holder possessed such
information or could acquire it without unreasonable effort or expense) necessary to verify the accuracy of any information furnished to it or which it had access. The foregoing, however, does not limit or modify the representations or warranties of
Holder in this Agreement or the right of Motient to rely upon such representations or warranties. Motient has not received, nor is it relying on, any representations from Holder, other than as provided herein. 

Section 3.20     Investor Status; etc. Motient and Sub each certify and represent to Holder that it is an “accredited investor” as defined in Rule 501 of Regulation D promulgated under the Securities Act and was not organized for the
purpose of acquiring the TerreStar Shares. Motient’s financial condition is
such that it is able 

12

to bear the risk of holding the TerreStar
Shares for an indefinite period of time and the risk of loss of its entire investment. Motient has sufficient knowledge and experience in investing in companies similar to TerreStar so as to be able to evaluate the risks and merits of its investment
in TerreStar. 

Section 3.21   Brokers or Finders.  Except for fees which shall be borne solely by Motient, neither Motient nor Sub has incurred, nor will either of them incur, directly or indirectly, any liability for brokerage or finders’ fees or
agents’ commissions or investment bankers’ fees or any similar charges in connection with this Agreement or any transaction contemplated hereby. 

Section 3.22   Restricted Securities. Motient understands that the TerreStar Shares may not be sold, transferred or otherwise disposed of without registration under the Securities Act or an exemption therefrom, and that in the absence of an
effective registration statement covering the TerreStar Shares or an available exemption from registration under the Securities Act, such TerreStar Shares must be held indefinitely. In particular, Motient is aware that such TerreStar Shares may not
be sold pursuant to Rule 144 or Rule 145 promulgated under the Securities Act unless all of the conditions of the applicable rule are met. Among the conditions for use of Rules 144 and 145 is the availability of current information to the public
about TerreStar. 

Section 3.23   Issuances Exempt. Assuming the truth and accuracy of the representations and warranties of Holder contained in Article II hereof, the offer, sale, and issuance of the Motient Shares will be exempt from the registration
requirements of the Securities Act, and will have been registered or qualified (or are exempt from registration and qualification) under the registration, permit or qualification requirements of all applicable state securities laws. 

Section 3.24   No Integrated Offering. Neither Motient, nor any of its affiliates or any other person acting on Motient’s behalf, has directly or indirectly engaged in any form of general solicitation or general advertising with respect to
the Motient Shares nor have any of such persons made any offers or sales of any security or solicited any offers to buy any security under circumstances that would require registration of the Motient Shares under the Securities Act or cause this
offering of the Motient Shares to be integrated with any prior offering of securities of Motient for purposes of the Securities Act. 

ARTICLE IV

ADDITIONAL AGREEMENTS

Section 4.1     HSR Act and FCC Approval. The parties will promptly execute and file, or join in the execution and filing of, any application, notification (including any notification or provision of information, if any, that may be required
under the HSR Act, which the parties shall file no later than 15 business days
after the date hereof) or other document that may be necessary in order to
obtain the authorization, approval or consent of any Governmental Entity, which
may be reasonably required in connection with the consummation of the
transactions contemplated by this Agreement. Any fees associated with such
notifications or applications shall be borne by Motient. Each party will use
commercially reasonable efforts to obtain, or assist the other parties in
obtaining, all such authorizations, approvals and consents, including without
limitation using commercially 

13

reasonable efforts to supply as promptly as practicable any additional
information
and documentary material that may be requested pursuant to the HSR Act and to request the expiration or termination of the applicable waiting periods under the HSR Act as soon as practicable. Each party shall, in connection with its obligation to
use commercially reasonable efforts to obtain, or assist the other parties in obtaining, all such requisite authorizations, approvals or consents, use commercially reasonable efforts to (i) cooperate in all reasonable respects with the other parties
in connection with any filing or submission and in connection with any investigation or other inquiry, including any proceeding initiated by a private party, (ii) promptly inform the other parties of any communication received by such party from or
given by such party to, the United States Department of Justice (the “DOJ”), the United States Federal Trade Commission (the “FTC”), the FCC or any other Governmental Entity or quasi-governmental
entity and of any material communication received or given in connection with any proceeding by a private party, in each case regarding any of the transactions contemplated hereby, (iii) permit the other parties, or the other parties’ legal
counsel, to review any communication given by it to, and consult with the other parties in advance of any meeting or conference with, the DOJ, the FTC, the FCC or any such other Governmental Entity or quasi-governmental entity or, in connection with
any proceeding by a private party, with any other person and (iv) to the extent permitted by the FCC or other Governmental Entity, as appropriate, give the other parties the opportunity to attend and participate in such meetings and conferences.

Section 4.2     Blue Sky Laws. Motient shall exercise its commercially reasonable best efforts to register or qualify (or obtain an exemption from registration) the Motient Shares under the blue sky laws of the 50 states of the United States and
of the District of Columbia and such other jurisdictions as Holder shall reasonably request, such registration, qualification or exemption to be obtained prior to the issuance and delivery to Holder of the Motient Shares in accordance with this
Agreement; provided, however, that, in the case of non-U.S. jurisdictions, Motient will not be required to (a) qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 4.2, (b)
subject itself to taxation in any such jurisdiction or (c) consent to general service of process in any such jurisdiction). Motient shall pay for all fees (including filing and application fees), costs and expenses in connection therewith. However,
the failure to obtain such “blue sky” clearance in each such jurisdiction shall not be a condition to closing and shall not prevent a Closing from occurring; provided, that Motient shall not fail to obtain such “blue sky”
clearance in (i) more than five such jurisdictions, (ii) Texas or (iii) New York; rather, those Motient Shares which may not be lawfully delivered shall be held in trust by Holder or its nominee for the benefit of the stockholders of record
otherwise entitled thereto until such time as they may be lawfully delivered.  If, after the fifth anniversary of the Closing, such shares still may not be lawfully delivered, then Motient shall deliver such shares to the government agency or
official responsible for administering the securities or blue sky laws in such jurisdiction. Holder shall cooperate with and assist Motient in connection with obtaining the “blue sky” clearance contemplated by this Section 4.2. 

Section 4.3     Compliance with TerreStar Documents.  The parties intend that this Agreement and the transactions contemplated thereby be consistent with the conditions and restrictions applicable to the parties and/or their affiliates pursuant
to TerreStar’s organizational documents and/or pursuant to the agreements between or among TerreStar’s stockholders, including, without limitation, the TerreStar Documents (collectively, the “TerreStar Investor
Agreements”). Each of Holder, Sub and Motient shall take all
commercially reasonable actions
necessary to comply with, or appropriately amend, the provisions of the TerreStar Investor Agreements relating to the sale of the TerreStar Shares pursuant hereto.

14

Section 4.4     No Transfers; No Alternative Transactions.

(a)     Holder shall not, and shall cause its subsidiaries and the officers, directors, employees, representatives (including, without limitation, investment bankers, attorneys and accountants), agents or Affiliates of Holder and its subsidiaries not
to, directly or indirectly, (i) solicit, initiate, encourage or facilitate any inquiries or the making of a proposal or offer with respect to, or consummate, an Alternative Proposal, (ii) participate in any discussions or negotiations with, or
provide any non-public information to, or afford any access to the properties, books or records of TerreStar, or otherwise take any other action to assist, facilitate or undertake (including granting any waiver or release under any standstill or
similar agreement with respect to any securities of TerreStar), by itself or with any “person” or “group” (as such terms are used for purposes of Section 13(d)(3) of the Exchange Act), any Alternative Proposal, or (iii) acquire,
of record or beneficially, or have, by conversion, warrant, option or otherwise, any right or interest in or any agreement to acquire any shares of TerreStar common stock, other than the TerreStar Shares owned as of the date hereof.
“Alternative Proposal” shall mean (a) any offer or proposal, or any indication of interest in making an offer or proposal, made by any “person” or “group” (as such terms are used for purposes of Section
13(d)(3) of the Exchange Act) at any time, directly or indirectly, to acquire the TerreStar Shares, (b) directly or indirectly sell, transfer, distribute, pledge, dispose of, grant an option with respect to or encumber the TerreStar Shares, or (c)
deposit the TerreStar Shares into a voting trust or enter into a voting agreement or arrangement with respect to the TerreStar Shares or grant any proxy with respect thereto, in each case other than the transactions contemplated by this
Agreement.

(b)     Except for transactions contemplated or permitted by this Agreement, Holder shall not, from the date hereof until the earlier of the termination of this Agreement or the Closing, (x) acquire, announce an intention to acquire, offer to acquire,
or enter into any agreement, arrangement or undertaking of any kind the purpose of which is to acquire, by purchase, exchange or otherwise, any shares of Motient Common Stock or any security or obligation that is by its terms, directly or
indirectly, convertible into or exchangeable or exercisable for shares of Motient Common Stock, and any option, warrant or other subscription or purchase right with respect to Motient Common Stock, whether by tender offer, market purchase, privately
negotiated purchase, merger or otherwise, or (y) form, join or in any way participate in a “group” (within the meaning of Section 13(d)(3) of the Exchange Act) or otherwise act in concert with any person in connection with such actions. 

Section 4.5     Commercially Reasonable Efforts. The parties shall each cooperate with each other and use (and shall cause their respective subsidiaries to use) their respective commercially reasonable efforts to promptly (i)
take or cause to be taken all necessary actions, and do or cause to be done all
things, necessary, proper or advisable under this Agreement or the TerreStar
Agreements and applicable laws to consummate and make effective all the
transactions contemplated by this Agreement as soon as practicable, including,
without limitation, preparing and filing promptly and fully all documentation to
effect all necessary filings, notices, petitions, statements, registrations,
submissions of information, applications and other documents and (ii) obtain 

15

all approvals required to be obtained from any Governmental Entity or third
party
necessary, proper or advisable to the transactions contemplated by this Agreement. Holder shall at any time, and from time to time, after the Closing, execute, acknowledge and deliver all further assignments, transfers, and any other such
instruments of conveyance, upon the request of Motient, to confirm the sale of the TerreStar Shares hereunder. 

Section 4.6     Public Announcements. Except as may be required by applicable law, no party hereto shall make any public announcements or otherwise communicate with any news media with respect to this Agreement or any of the transactions
contemplated hereby, without prior consultation with the other parties as to the timing and contents of any such announcement or communications; provided, however, that nothing contained herein shall prevent any party from promptly making all
filings with any Governmental Entity or disclosures with the stock exchange, if any, on which such party’s capital stock is listed, as may, in its judgment, be required in connection with the execution and delivery of this Agreement or the
consummation of the transactions contemplated hereby. 

ARTICLE V

CONDITIONS TO CLOSING OF MOTIENT AND SUB

The obligation of Sub to purchase the TerreStar Shares from Holder, and to issue to Motient Shares to Holder, at the Closing is subject to the fulfillment to Motient and Sub’s satisfaction or the waiver by Motient on or prior to the Closing
Date of each of the following conditions: 

Section 5.1     Representations and Warranties. Each representation and warranty made by Holder in Article II above shall be true and correct in all material respects on and as of the Closing Date as though made on the Closing Date, except that
any such representation and warranty that is given as of a particular date or period and relates solely to such particular date or period shall be true and correct in all material respects only as of such date or period, provided, however, that any
representations and warranties which by their terms are qualified by materiality which shall be true and correct in all respects, with the same force and effect as if such representation and warranty had been made on and as of the Closing Date. 

Section 5.2     Performance. All covenants, agreements and conditions contained in this Agreement to be performed or complied with by Holder on or prior to the Closing Date shall have been performed or complied with by Holder in all respects. 

Section 5.3     Intentionally Omitted 

Section 5.4     Certificates and Documents. Holder shall have delivered at or prior to the Closing to Motient or Sub, as applicable, the Holder Closing Deliveries. 

Section 5.5     Compliance Certificate.  Holder shall have delivered to Motient or its counsel a certificate signed by Holder or an authorized representative of Holder, as applicable, dated the Closing Date, certifying to the fulfillment of the
conditions specified in Sections 5.1 and 5.2 above. 

16

Section 5.6     Final Order of FCC and Industry Canada Approval. All necessary FCC and Industry Canada approvals shall have been obtained without the imposition on Motient of any material adverse conditions and such approvals shall have become
Final Orders and shall be in full force and effect, provided that Motient may waive the condition that the approvals have become Final Orders. For the purpose of this Agreement, “Final Order” means an action by the FCC that has not been
reversed, stayed, enjoined, set aside, annulled or suspended within forty days after being obtained. 

Section 5.7     Intentionally Omitted 

Section 5.8     Intentionally Omitted.

Section 5.9     FIRPTA Certificate.  Holder shall have furnished Motient an affidavit certifying as to Holder’s non-foreign status in accordance with the requirements of Section 1.1445 -2(b) of the Internal Revenue Service Treasury
Regulations. 

Section 5.10   Amended TerreStar Stockholders’ Agreement.  The Amended TerreStar Stockholders’ Agreement shall be effective. 

Section 5.11   MSV Exchange Agreement.  All actions necessary to consummate the closing of the transactions contemplated by Exchange Agreement dated as of the date hereof by and among Motient, SkyTerra Communications, Inc. and Motient Ventures
Holdings Inc. shall have been taken. 

Section 5.12   Columbia/Spectrum Exchange Agreements.  All actions necessary to consummate the closing of the transactions contemplated by Exchange Agreements dated as of May 6, 2006 by and among Motient, Sub and each of Columbia Capital Equity
Partners III (QP), L.P., Columbia Capital Equity Partners III (AI), L.P., Columbia Capital Equity Partners III (Cayman), L.P., Columbia Capital Investors III, LLC, Columbia Capital Employee Investors III, L.L.C., Spectrum Equity Investors Parallel
IV, L.P., Spectrum IV Investment Managers' Holder, L.P. (collectively, the “Funds”) shall have been taken. 

ARTICLE VI

CONDITIONS TO CLOSING OF FUND

The obligation of Holder to purchase the Motient Shares from Motient, and to transfer the TerreStar Shares to Motient, at the Closing is subject to the fulfillment to Holder’s satisfaction on or prior to the Closing Date of each of the
following conditions: 

Section 6.1     Representations and Warranties. Each representation and warranty made by Motient and Sub in Article III above shall be true and correct in all material respects on and as of the Closing Date as though made on the Closing Date,
except that any such representation and warranty that is given as of a particular date or period and relates solely to such particular date or period shall be true and correct in all material respects only as of such date or period, provided,
however, that any representations and warranties which by their terms are qualified by materiality which shall be true and correct in all respects, with the same force and effect as if such representation and warranty had been made on and as of the
Closing Date. 

17

Section 6.2     Performance. All covenants, agreements and conditions contained in this Agreement to be performed or complied with by Motient and Sub on or prior to the Closing Date shall have been performed or complied with by Motient or Sub, as
applicable, in all respects. 

Section 6.3     Opinion of Motient’s Counsel. Holder shall have received at the Closing from Andrews Kurth LLP, counsel to Motient, an opinion in substantially the form attached as Exhibit C hereto dated as of the Closing Date. 

Section 6.4     Certificates and Documents. Motient shall have delivered at or prior to the Closing to Holder the Motient Closing Deliveries. 

Section 6.5     Compliance Certificate.  Motient shall have delivered to Holder or its counsel a certificate signed by the Chief Operating Officer of Motient, dated the Closing Date, certifying to the fulfillment of the conditions specified in
Sections 6.1 and 6.2 above. 

Section 6.6     FCC and Industry Canada Approvals.  All necessary FCC and Industry Canada approvals shall have been obtained and shall be in full force and effect. 

Section 6.7     Intentionally Omitted 

Section 6.8     Effective Registration Statement.  The Registration Statement shall have become and continue to be effective and no stop order with respect thereto shall be in effect and no proceedings for that purpose shall have been commenced
or threatened by the SEC. 

Section 6.9     Registration Rights Agreement. The Registration Rights Agreement shall be in full force and effect and shall be binding on Motient. 

Section 6.10   Holder Exchange Agreements.  Motient shall have taken all actions necessary to consummate the closing under each of the exchange agreements between Motient and each of the Funds. 

ARTICLE VII 

INDEMNIFICATION 

Section 7.1     Survival of Representations and Warranties.  The warranties, representations, covenants and agreements of Holder, Motient and Sub contained in this Agreement shall survive the execution and delivery of this Agreement and the
Closing for a period of twelve (12) months (the “Survival Period”), and shall in no way be affected by any investigation of the subject matter thereof made by any party hereto.

Section 7.2     Obligation to Indemnify.

(a)     Holder’s Obligation to Indemnify.  From and after the Closing, Holder shall indemnify, defend and hold harmless Motient, Sub and their respective officers, directors, stockholders, partners, employees, subsidiaries, agents and
affiliates (each, a “Motient Indemnitee”), from and against
all losses, claims, damages, liabilities, obligations, fines, penalties,
judgments, settlements, costs, expenses and disbursements (including

18

attorneys’,
accountants’ and investigatory fees and expenses) (collectively, “Losses”) to the extent resulting from any (i) breach or inaccuracy of any representation or warranty of Holder contained in the Agreement for which a
claim is initiated prior to the expiration of the applicable Survival Period or (ii) non-fulfillment or breach of any covenant or agreement of Holder contained in this Agreement.

(b)     Motient’s Obligation to Indemnify. From and after the Closing Date, Motient and Sub, jointly and severally, shall indemnify, defend and hold harmless Holder and its officers, directors, stockholders, managers, partners, members,
employees, agents and affiliates (each, a “Holder Indemnitee”) from and against any and all Losses to the extent resulting from any (i) breach or inaccuracy of any representation or warranty of Motient or Sub contained in
this Agreement for which a claim is initiated prior to the expiration of the applicable Survival Period or (ii) non-fulfillment or breach of any covenant or agreement of Motient or Sub contained in this Agreement .

(c)     Indemnification Basket Amount.  Notwithstanding the foregoing, an Indemnifying Party (defined below) shall not be required to indemnify an Indemnified Party (defined below) pursuant to Section 7.2(a) or Section 7.2(b), as
applicable, unless and until the amount of all Losses incurred by such Indemnified Party exceeds $1,000,000 in the aggregate (the “Basket Amount”), in which case the Indemnifying Party shall be required to
indemnify the Indemnified Party for any and all such Losses in excess of the Basket Amount; provided, however, that the limitation set forth in this Section 7.2(c) shall not apply to Losses resulting from a breach of the representations and
warranties set forth in Sections 2.2, 2.10, 3.2(b) or 3.21.

Section 7.3     Indemnification Procedures.

(a)     The person seeking indemnification hereunder (each, an “Indemnified Party”) shall give the party or parties from whom indemnification is sought or to be sought (each, an “Indemnifying Party”)
prompt written notice of any Loss as to which they have received written notification. If an indemnification claim involves a claim by a third party (a “Third Party Claim”), the Indemnified Party shall promptly notify the
Indemnifying Party thereof in writing; provided, however, that no delay on the part of the Indemnified Party in notifying the Indemnifying Party shall relieve the Indemnifying Party from any obligation hereunder unless (and then solely to the
extent) the Indemnifying Party is actually and materially prejudiced thereby.  An Indemnifying Party shall have ten business days from the delivery of such notice (the “Notice Response Period”) to notify the Indemnified Party
whether or not it disputes its liability to the Indemnified Party hereunder with respect to such claim or demand. If an Indemnifying Party disputes its liability to an Indemnified Party hereunder with respect to such claim or demand or the amount
thereof, such dispute shall be resolved by a civil action in a court of appropriate jurisdiction (including as part of any proceeding with respect to the claim that gave rise to the indemnification claim to which such dispute relates) which may be
commenced by either party. During the Notice Response Period, no such claim or demand may be settled by the Indemnified Party. 

(b)     With respect to each Indemnification Matter (as
defined below), the Indemnified Parties will have the sole right and authority
to control the defense against any Third Party Claim with one counsel of their 

19

collective choice. This right shall include the right to settle
or resolve the Third Party Claim by entering into an agreement memorializing the terms of settlement or resolution (a “Settlement Agreement”), provided however, that the Indemnified Party provides the Indemnifying Party with
notice (in accordance with Section 7.4 hereof) of its intent to enter into a Settlement Agreement, which notice shall include the proposed terms of the Settlement Agreement. The Indemnifying Party shall, within ten business days of receipt of
such notice, have the right to reject the proposed Settlement Agreement, but shall do so only if it reasonably determines that the Settlement Agreement does not represent a bona fide and reasonable resolution of the underlying Third Party Claim.
The Indemnifying Party (and any Indemnified Party who is not otherwise satisfied with the one counsel chosen by the Indemnified Parties collectively) may retain separate co-counsel at their sole cost and expense and participate in the defense of the
Third Party Claim; provided, however, that in no event may any Indemnifying Party consent to the entry of any judgment, enter into any settlement with respect to the Third Party Claim or agree with any Person other than the Indemnified Party, to
take any other action with respect to the Third Party Claim without the prior written consent of the Indemnified Party.  If it is determined pursuant to an order or Settlement Agreement that an Indemnifying Party is responsible for all or a portion
of any amounts for which the Indemnified Party is liable as a result of such Third Party Claim hereunder, the Indemnifying Party shall, pursuant to Section 7.4(b), render payment to the Indemnified Party for all Losses resulting from such
claim, subject to the provisions of Section 7.5. 

Section 7.4     Notices and Payments.

With respect to each separate matter which is subject to indemnification under this Article VII (each, an “Indemnification Matter”): 

(a)     Notice.  Upon the Indemnified Party’s receipt of written documents pertaining to an Indemnification Matter, or, if the Indemnification Matter does not involve a third party demand or claim, within a reasonable time after the
Indemnified Party first has actual knowledge of such Indemnification Matter, the Indemnified Party shall give written notice to the Indemnifying Party of the nature of such Indemnification Matter, and, if susceptible to estimation at such time, the
Indemnified Party’s best estimate of the amount demanded or claimed in connection therewith as provided in Section 7.3; provided, however, that no delay on the part of the Indemnified Party in notifying the Indemnifying Party shall
relieve the Indemnifying Party from any obligation hereunder unless (and then solely to the extent) the Indemnifying Party is actually and materially prejudiced thereby. 

(b)     Payment. Upon determination of the amount of the Loss (whether due to the Indemnifying Party’s failure to dispute the indemnification matter, by agreement among the parties, or after a settlement agreement is executed or a final
order is rendered with respect to the indemnification matter), the Indemnifying Party shall promptly (and in any event, not later than ten days after such determination) pay to the Indemnified Party all amounts owing by the Indemnifying Party under
this Article VII with respect to such indemnification matter, subject to the limitations set forth in Section 7.5. 

Section 7.5     Limited Remedy.

20

(a)     Motient Indemnitee Indemnification Limit. Except in the case of fraud or where specific performance is sought, the maximum amount all Motient Indemnitees may recover in the aggregate pursuant to the indemnity set forth in Section
7.2(a) hereof with respect to the Closing shall be limited to the value of the Motient Shares based on the average of the high and low sales price for the five trading day period immediately prior to, and including, the Closing Date. 

(b)     Holder Indemnitee Indemnification Limit. Except in the case of fraud or where specific performance is sought, the maximum amount all Holder Indemnitees may recover in the aggregate pursuant to the indemnity set forth in Section
7.2(b) hereof with respect to the Closing shall be limited to the value of the Motient Shares based on the average of the high and low sales price for the five trading day period immediately prior to, and including, the Closing Date. 

ARTICLE VIII 

MISCELLANEOUS 

Section 8.1     Termination. This Agreement may be terminated prior to the Closing as follows: 

(i)     at any time on or prior to the Closing Date, by mutual written consent of Motient and Holder; 

(ii)     at the election of Motient or Holder by written notice to the other parties hereto after 5:00 p.m., New York time, on December 31, 2006, if the Closing shall not have occurred, unless such date is extended by the mutual written consent of
Motient and Holder; provided, however, that the right to terminate this Agreement pursuant to this clause (ii) shall not be available to a party whose failure or whose affiliate's failure to perform or observe in any material respect any of its
obligations under this Agreement in any manner shall have been the principal cause of the failure of the Closing to occur on or before such date; 

(iii)     at the election of Motient, if there has been a material breach of any representation, warranty, covenant or agreement on the part of Holder contained in this Agreement, which breach has not been cured within fifteen (15) days of notice to
Holder of such breach; or 

(iv)     at the election of Holder, if there has been a material breach of any representation, warranty, covenant or agreement on the part of Motient or Sub contained in this Agreement, which breach has not been cured within fifteen (15) days notice to
Motient or Sub, as applicable, of such breach. 

Section 8.2     Survival.  If this Agreement is terminated and the transactions contemplated hereby are not consummated as described above, this Agreement shall become void and of no further force and effect, except for the provisions of this
Section 8.2 and Sections 8.3 through 8.13 (inclusive); provided, however, that (a) none of the parties hereto shall have any liability in respect of a termination of this Agreement pursuant to Section
8.1

21

(i), or Section 8.1(ii), (b) nothing shall relieve any of the parties from liability for actual damages resulting from a breach of any representation, warranty, covenant or agreement which gave rise to a termination of this Agreement pursuant to
Section 8.1(iii) or 8.1(iv).

Section 8.3     Expenses.  Whether or not the transactions contemplated hereby are consummated, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby and thereby shall be paid by the party
incurring such expenses. 

Section 8.4     Counterparts; Effectiveness. This Agreement may be executed in two or more consecutive counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument,
and shall become effective when one or more counterparts have been signed by each of the parties and delivered (by facsimile or otherwise) to the other parties. 

Section 8.5     Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York without regard to the principles of conflicts of laws thereof. 

Section 8.6     Notices.  Any notices, reports or other correspondence (hereinafter collectively referred to as “correspondence”) required or permitted to be given hereunder shall be given in writing and shall be deemed given three
business days after the date sent by certified or registered mail (return receipt requested), one business day after the date sent by overnight courier or on the date given by facsimile (with confirmation of receipt) or delivered by hand, to the
party to whom such correspondence is required or permitted to be given hereunder. 

To Motient or Sub: 

Motient Corporation 

300 Knightsbridge Parkway

Lincolnshire Parkway 

Lincolnshire, IL 60069 

Facsimile: (847) 478-4810 

Attention: General Counsel

with a copy (which shall not constitute notice) to:

Andrews Kurth LLP 

600 Travis Street, Suite 4200

Houston, Texas 77002 

Facsimile: (713) 220-4285 

Attention: Mark Young

 

To Holder: 

[ADDRESS]

22

Section 8.7     Assignment; Binding Effect. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the parties hereto without the prior written consent of the other parties. Subject to the
preceding sentence, this Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns. 

Section 8.8     Severability. Any term or provision of this Agreement which is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective to the extent of such invalidity or unenforceability without rendering
invalid or unenforceable the remaining terms and provisions of this Agreement in any other jurisdiction. If any provision of this Agreement is so broad as to be unenforceable, such provision shall be interpreted to be only so broad as is
enforceable. 

Section 8.9     Entire Agreement; Non-Assignability; Parties in Interest. This Agreement and the documents and instruments and other agreements specifically referred to herein or delivered pursuant hereto, including the Exhibits and the Motient
Disclosure Schedule: (a) constitute the entire agreement among the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, both written and oral, among the parties with respect to the subject matter
hereof; (b) are not intended to confer upon any other person (except the Motient Indemnitees and the Holder Indemnitees) any rights or remedies hereunder and (c) shall not be assigned by operation of law or otherwise except as otherwise specifically
provided. Without limiting the foregoing, no party shall be deemed to have made any representation or warranty other than as expressly made herein. 

Section 8.10   Headings. Headings of the Articles and Sections of this Agreement are for convenience of the parties only, and shall be given no substantive or interpretive effect whatsoever. 

Section 8.11     Certain Definitions.  References in this Agreement to “subsidiaries” of Holder or Motient shall mean any corporation or other form of legal entity of which more than 50% of the outstanding voting securities are on the
date hereof directly or indirectly owned by Holder or Motient, as the case may be.  References in this Agreement (except as specifically otherwise defined) to “affiliates” shall mean, as to any person, any other person which, directly or
indirectly, controls, or is controlled by, or is under common control with, such person. As used in this definition, “control” (including, with its correlative meanings, “controlled by” and “under common control with”)
shall mean the possession, directly or indirectly, of the power to direct or cause the direction of management or policies of a person, whether through the ownership of securities or partnership of other ownership interests, by contract or
otherwise. References in the Agreement to “person” shall mean an individual, a corporation, a partnership, an association, a trust or any other entity or organization, including, without limitation, a Governmental Entity.
“Antitrust Laws” means the HSR Act, the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other United States federal or state or foreign statutes, rules, regulations,
orders, decrees, administrative or judicial doctrines or other laws that are designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade. 

23

Section 8.12   Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with
the written consent of each of the parties hereto. 

Section 8.13   Specific Performance.  The parties to this Agreement agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise
breached. Accordingly, the parties to this Agreement hereby agree that each party hereto shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement
in any court of the United States or any state having jurisdiction, in addition to any other remedy to which such party may be entitled at law or in equity. 

Section 8.14   Exclusive Jurisdiction. Any suit, action or proceeding seeking to enforce any provision of, or based on any matter arising out of or in connection with, this Agreement or the transactions contemplated hereby may only be brought
in any federal or state court located in the County and State of New York, and each of the parties hereby consents to the exclusive jurisdiction of such courts (and of the appropriate appellate courts therefrom) in any such suit, action or
proceeding and irrevocably waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of the exclusive venue of any such suit, action or proceeding in any such court or that any such suit, action
or proceeding which is brought in any such court has been brought in an inconvenient forum. Process in any such suit, action or proceeding may be served on any party anywhere in the world, whether within or without the jurisdiction of any such
court. Without limiting the foregoing, each party agrees that service of process on such party as provided in Section 9.6 shall be deemed effective service of process on such party. 

Section 8.15   Waiver of Jury Trial.  EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. 

[Signature Pages Follow]

24

IN WITNESS WHEREOF, the parties hereto have caused this Exchange Agreement to be duly executed and delivered as of the date first above written. 

	MOTIENT CORPORATION
	 	 
	By:	 
	 	Christopher Downie 
	 	Executive Vice President and Chief

		Operating Officer 
	 	 

	MVH HOLDINGS INC.
	 	 
	By:	 
	Name:	Christopher Downie 
	Title:	Executive Vice President

[Signature Page to Exchange Agreement]

	HOLDER
	 	 
	By:	 
	Name:	 
	Title:	 

 
[Signature Page to Exchange Agreement]Exhibit 10.47

                          CONSULTING SERVICES AGREEMENT

This AGREEMENT ("AGREEMENT") is entered into as of  August 1-, 2006, by DNAPrint
genomics,  Inc.,  900  Cocoanut  Ave.,  Sarasota, FL 34236, USA ("DNAP") and DR.
ARTHUR J. SYTKOWSKI residing at 203 Park Avenue, Arlington, Massachusetts 02476,
USA  ("DR.  SYTKOWSKI").

                                   WITNESSETH:

     WHEREAS,  DNAP  is  engaged  in a project (the "PROJECT") relating to human
erythropoietin  (the  "FIELD");  and

     WHEREAS, DR. SYTKOWSKI has knowledge and expertise regarding the FIELD; and

     WHEREAS,  DNAP  desires  to  make  use  of  the  specialized  knowledge and
expertise  of  DR.  SYTKOWSKI  as  a  consultant  in  the  FIELD;  and

     WHEREAS,  DR.  SYTKOWSKI  has  advised DNAP of his willingness, ability and
desire  to provide consulting and advisory services to it in connection with the
FIELD;

NOW,  THEREFORE,  in  consideration  of  the  mutual  covenants  and  conditions
contained  herein,  DR.  SYTKOWSKI  and  DNAP  agree  as  follows:

1.  ENGAGEMENT  -  DNAP  hereby  engages  DR. SYTKOWSKI and DR. SYTKOWSKI hereby
    ----------
agrees  to hold himself available and to render, at DNAP's  request, independent
   --
advisory  and  consulting  services, in compliance with the terms and conditions
set  forth  herein  and  all  applicable  laws,  statutes  and  regulations.

2.  SERVICES  AND  DUTIES  -  DR.  SYTKOWSKI agrees that during the term of this
    ---------------------
AGREEMENT and any subsequent extension(s) thereof,  he will provide his services
   --
as  a  consultant  to  DNAP in the FIELD. DR. SYTKOWSKI's responsibilities shall
include,  but  shall  not  be  limited  to,  the  following  services:

a. Consulting on all matters involving the FIELD, including, without limitation,
implementation  of  analytics, purification, medical uses, regulatory issues and
patent  affairs;

b.  Advising  and training personnel designated by DNAP in the FIELD technology;

c.  Advising  on  the  status  of  FIELD-  related  patents  and  prosecutions;

d.  Advising  on  clinical  trials,  medical uses and side effects of the FIELD;

e.  Providing  information  on  new  developments  in  the  FIELD;

f. Providing expertise and introduction to  DR. SYTKOWSKI's personal contacts in
the  FIELD,  including  without  limitation,  scientific,  medical,  biotech,
regulatory  and  patent  issues;  and,

g.  Working  on  the  Tasks  described  on  the  attached  Exhibit  "A".

DR.  SYTKOWSKI further agrees to render his services conscientiously, consistent
with the highest standards of his profession, and to devote, subject to existing
professional  duties,  the  requisite  time,  effort  and  abilities required to
satisfactorily perform his obligations during the term of this AGREEMENT and any
subsequent  extension(s) thereto, and to do so in such reasonable manner as DNAP
and  DR.  SYTKOWSKI  shall  mutually  agree.

3.  PAYMENT  - As full consideration for the services performed by DR. SYTKOWSKI
    -------
hereunder,  DNAP  agrees  to  compensate  DR.  SYTKOWSKI  as  follows:

     a.  ONE  HUNDRED AND TWENTY THOUSAND ($ 120,000.00) U.S. DOLLARS to be paid
in  twelve equal monthly installments of TEN THOUSAND ($10,000.00) U.S. DOLLARS.
Each  payment  will  be  made  within  THIRTY (30) DAYS of the first day of each
month,  with  the  first  month  commencing  on  the  date  of execution hereof.

     b.  Upon  presentation  of  receipts, DNAP will reimburse DR. SYTKOWSKI for
reasonable out-of-pocket expenses incurred in connection with services performed
under  this  AGREEMENT,  including  but  not limited to airfare, lodging, meals,
taxis,  trains,  extraordinary fee-based computer searches and the like. Flights
of  greater  than  two (2) hours will be business class or the next higher class
above  economy, if DR. SYTKOWSKI so chooses. DR. SYTKOWSKI will invoice DNAP for
such  travel  and  other expenses promptly after incurring such charges and DNAP
agrees to pay such invoices, subject to the conditions of this paragraph, within
THIRTY  (30)  DAYS  of  their  receipt.

     c.  DNAP  agrees  to  reimburse  DR. SYTKOWSKI for airfare, lodging, meals,
taxis,  trains,  and  all  other  reasonable  out-of-pocket expenses incurred in
conjunction  with  attending  two  scientific/medical,  biotechnology  or
pharmaceutical  related  meetings  per year, said meetings to relate directly to
the  FIELD and/or to DR. SYTKOWSKI's consulting and advisory services under this
AGREEMENT.  DR.  SYTKOWSKI  shall  obtain DNAP's consent prior to incurring such
expenses.  DR.  SYTKOWSKI  agrees  to invoice DNAP promptly after incurring such
charges  and  DNAP  agrees to pay such invoices within THIRTY (30) DAYS of their
receipt.

     d.  In  recognition  of DR. SYTKOWSKI's knowledge and skill, DNAP agrees to
make  five  separate  incentive  payments to DR. SYTKOWSKI at the rate of TWENTY
FIVE  THOUSAND  ($25,000.00)  U.S. DOLLARS per year to be paid on or before each
anniversary  of  the  date  of  execution  hereof.

4.  MILESTONE  CONTINGENT  PAYMENTS- DNAP agrees to make the following milestone
  ---------------------------------
payments to DR. SYTKOWSKI following the completion of the described event to the
satisfaction  of  DNAP,  and  to  the  extent DR. SYTKOWSKI has not received any
monies  from Beth Israel Deaconess Medical Center ("BIDMC") under any agreements
between  DR.  SYTKOWSKI  and  BIDMC  relating  to  the  described  event:

a.     Initiation  of  the  first  Phase  I  trial  of  an  erythropoietin  or
erythropoietin-related  product, TWENTY FIVE THOUSAND ($25,000.00) U.S. DOLLARS.
b.     Initiation  of  the  first  Phase  II  trial  of  an  erythropoietin  or
erythropoietin-related  product, TWENTY FIVE THOUSAND ($25,000.00) U.S. DOLLARS.
c.     First  regulatory approval of an erythropoietin or erythropoietin-related
product,  TWENTY  FIVE  THOUSAND  ($25,000.00)  U.S.  DOLLARS.
d.     First  commercial  sale  of  an  erythropoietin or erythropoietin-related
product,  FIFTY  THOUSAND  ($50,000.00)  U.S.  DOLLARS.

DNAP's  obligation  to  make these payments to DR. SYTKOWSKI will extend for ten
(10)  years  beyond  the  term of this AGREEMENT, or any termination, renewal or
extension  thereof.  Any  payments DR. SYTKOWSKI receives from BIDMC relating to
the  described  events  shall  reduce,  dollar  for  dollar,  DNAP's obligations
hereunder.

5.  INDEMNIFICATION  -  DNAP  shall  indemnify,  defend  and  hold  harmless DR.
    ---------------
SYTKOWSKI  and  his  employees and agents and their respective heirs, successors
   -----
and assigns (the "INDEMNITEES"), against any liability, damage, loss, or expense
(including  attorneys'  fees and expenses of litigation) actually incurred by or
imposed  upon  the INDEMNITEES or any one of them in connection with any claims,
suits,  actions,  demands, or judgments of any party other than DNAP arising out
of  or  relating  to  the  PROJECT, including, but not limited to, any theory of
product  liability  (including  but not limited to, strict liability) concerning
any  products,  process  or  service  made,  used or sold pursuant to any rights
granted  under  this  AGREEMENT.  DNAP's  indemnification shall not apply to any
claim,  suit,  action,  demand,  loss  or expense (including attorneys' fees and
expenses of litigation) to the extent that it is actually incurred or imposed or
is  due  to the breach of this AGREEMENT, violation of or failure to comply with
any  law,  or  governmental  regulation,  negligence,  reckless  MISCONDUCT  or
intentional  MISCONDUCT  (hereinafter collectively the " MISCONDUCT ") of any of
the  INDEMNITEES.

6.  CONFIDENTIALITY  -  In  view of the proprietary rights and interests of DNAP
    ---------------
concerning the PROJECT and their facilities and technology, DR. SYTKOWSKI agrees
that  during the term of this AGREEMENT and any subsequent extension(s) thereto,
and  for  a  period  of  three (3) years thereafter, DR. SYTKOWSKI shall hold in
strictest  confidence  and not use for his own benefit or for the benefit of any
third  party  any  information concerning the PROJECT and DNAP (including DNAP's
security  and computer systems) or the FIELD which is disclosed to DR. SYTKOWSKI
by DNAP or that results from his services under this AGREEMENT. Such information
includes,  but  is  not  limited  to,  confidential  or proprietary information,
discoveries,  results,  methodology,  codes,  passwords,  materials, technology,
know-how,  financial  and  other  data,  both  technical  and non-technical. DR.
SYTKOWSKI  shall  not  disclose  nor  cause  nor  permit  to  be  disclosed such
information  to  any third party or use such information for any purpose, except
as  provided  herein,  without the prior written approval of DNAP. The foregoing
restrictions  and obligations of DR. SYTKOWSKI shall not apply to any portion of
such  information  which:

a.  Is or later becomes generally available to the public by use, publication or
the  like,  through  no  fault  of  DR.  SYTKOWSKI;

b.  Is  obtained from a third party who had the legal right to disclose the same
to  DR.  SYTKOWSKI;  or

c.  Is  already possessed by DR. SYTKOWSKI, as evidenced by his written records,
predating  receipt  thereof  from  DNAP.

Specific  information  disclosed to DR. SYTKOWSKI by DNAP shall not be deemed to
be  available  to  the  public  or  in  prior possession of DR. SYTKOWSKI merely
because  such  specific  information  is  embraced  by  more general information
available  to  the  public  or  in  the  prior  possession  of  DR.  SYTKOWSKI.

7.  RIGHT  TO  DISCLOSE  -  DR.  SYTKOWSKI  agrees  that during the term of this
    -------------------
AGREEMENT,  he  will  not  disclose  to DNAP any information which he is under a
   ----
contractual  or  other  legal  obligation  to  a  third  party  not to disclose.
   -

8.  TERM,  TERMINATION AND EXTENSION OF THIS AGREEMENT - This AGREEMENT shall be
    --------------------------------------------------
effective  for  a  twelve  (12) month Period beginning August 1, 2006 and ending
July  31,  2007.

Either  party  may terminate this AGREEMENT upon ninety (90) days written notice
to the other party. If DNAP terminates this AGREEMENT for DR. SYTKOWSKI's breach
of this AGREEMENT, or DR. SYTKOWSKI's violation of or failure to comply with any
law,  or  governmental regulation, negligence or MISCONDUCT, DR. SYTKOWSKI shall
not  be  entitled  to  receive  the  Milestone payments referenced in Section 4,
above.  Any  rights  or obligations set forth herein, which are accrued prior to
the  termination of this AGREEMENT, shall survive termination of this AGREEMENT.
Negotiations  may  be  initiated  at  the  request  of  either  party  prior  to
termination  of  this  AGREEMENT to extend this AGREEMENT. If the parties do not
agree  on  an  extension  in writing prior to July 15, 2006, the AGREEMENT shall
terminate  on  July  31,  2006.

9.  INDEPENDENT  CONTRACTOR  -  For the purpose of this AGREEMENT, DR. SYTKOWSKI
    -----------------------
shall  be an independent contractor of DNAP without the authority to bind or act
as  agent  for  DNAP  or  its  employees  for  any  purpose, and nothing in this
AGREEMENT shall be construed to create any joint venture or partnership among or
between  the  parties.

10.  PUBLICITY  -  Neither  party  will  use  the  name  of  the  other party in
     ---------
publication  or  advertising  involving this AGREEMENT without the other party's
    ------
prior  written  approval.

11.  WARRANTIES  -   The  parties warrant and represent that they have the right
     ----------
to  enter  into  and  perform this AGREEMENT. DR. SYTKOWSKI further warrants and
represents  that he knows of no conflict between the terms of this AGREEMENT and
any  other  contractual or other obligations, expressed or implied, which he may
have  with  anyone,  including but not limited to his contractual obligations to
Beth  Israel  Deaconess  Medical  Center.

12.  GOVERNING  LAW  -  This  AGREEMENT  shall  be  governed  by the laws of the
     --------------
Commonwealth  of Massachusetts, USA, and DR. SYTKOWSKI and DNAP hereby submit to
    ----
the  exclusive jurisdiction of the Massachusetts Courts, both State and Federal.

13.  AMENDMENTS  -  No  modification to this AGREEMENT shall be effective unless
     ----------
made  in  writing  and signed by a duly authorized representative of each party.

14.  NOTICES  - All notices required or permitted to be given hereunder shall be
     -------
in  writing  and given to each of the other parties hereto by delivery to its or
his  respective  address as first set forth above by (i) personal delivery, (ii)
courier  service  or registered or certified air mail (postage prepaid) or (iii)
by fax (with a copy by registered or certified air mail). All such notices shall
be  effective  when  received  by  the  addressee.

15. TAXES -Each party shall be responsible for his or its own tax obligations as
    -----
imposed  by  any  governmental  authority  having  jurisdiction.

16. ASSIGNMENT - This AGREEMENT may not be assigned without the parties' express
    ----------
written  consent.  Any  purported assignment of this AGREEMENT is void and of no
effect.

IN  WITNESS  WHEREOF,  the  parties have executed this AGREEMENT as of dates set
forth  below:

DR.  ARTHUR  J.  SYTKOWSKI               DNAPrint  genomics,  Inc.

Date:                                    Name  (print):

Place:                                   Date:

Signature:                               Place:

                                         Signature:

<PAGE>
                                    EXHIBIT A

The studies outlined below will require more than one year to complete. However,
each  study  can be emphasized depending upon priorities agreed upon by DNAP and
Dr.  Sytkowski.

  SUPERVISE STUDIES SUPPORTING EPO DIMER DEVELOPMENT AND PRODUCT DIFFERENTIATION
        COMPARING EPO DIMER, CONVENTIONAL EPO AND DARBEPOETIN (ARANESPTM)

-     Quantify  parameters  of  binding  to  the  Epo  receptor  (EpoR).

      o     On  and  off  rate  constants;  equilibrium  dissociation  constant
      o     Receptor  internalization  and  recycling  to  cell  surface
      o     Hill  coefficient

-     Quantify  intracellular  signal  strength  and  duration  for  growth  and
differentiation

-     Gene expression studies: compare qualitative and quantitative differences.

-     Compare  results  for  hematopoietic  cell  EpoR with EpoR on other cells,
e.g.,  endothelial  cells,  neuronal  cells.

-     Complete  development  of  anti-Epo  antibody  assays  required  by  FDA

-     Interact with CRO personnel including transfer of and training in analytic
techniques.

-     Carry  out  in  vitro  bioassays  of samples provided by CRO. The assay is
calibrated  against  the  World  Health  Organization  International  Reference
Preparation  of  human  erythropoietin.

-     Carry  out  in  vivo  bioassays  of  samples  provided  by  CRO

<PAGE>

    SUPERVISE RESEARCH AND DEVELOPMENT OF NEW PHARMACEUTICAL AGENTS BASED UPON
                               LICENSED TECHNOLOGY

-     Explore  polyethylene  glycol  derivatization  (PEGylation)  of  Epo dimer

      o     Test  alternative  chemistries
      o     Vary  stoichiometry
      o     Preliminary  PK  and  PD

-     Begin  development  of  R103A  mutant  for  tissue  protection (neuro- and
cardioprotection)

      o     Prepare  stably  expressing  CHO  cell  line
      o     Develop  in  vitro  assays  to  test  tissue  protective  effects
      o     Validate  R103A  as  a  tissue  protective  agent  in  vivo

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}]]